Ryoncil® is Now Available for Purchase in the United States
Portfolio Pulse from
Mesoblast Limited (MESO) has announced the commercial availability of Ryoncil®, the first FDA-approved mesenchymal stromal cell (MSC) therapy, for treating steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients. The company has established a patient access hub called MyMesoblast™ and is working with nine commercial payers representing approximately 37 million covered lives.
March 27, 2025 | 12:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
First FDA-approved MSC therapy now available, potentially opening significant market opportunity for Mesoblast in pediatric SR-aGvHD treatment
Commercial launch represents a significant milestone for Mesoblast, potentially driving revenue growth and demonstrating successful regulatory strategy. Nine commercial payers already on board suggests strong market potential.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100